?? la recherche de la mol??cule id??ale. Une br??ve histoire des anticoagulants, Revue des Maladies Respiratoires, vol.28, issue.8, pp.951-953, 2011. ,
DOI : 10.1016/j.rmr.2011.09.006
Admissions to hospital caused by adverse drug reactions: cross sectional incidence study, BMJ, vol.320, issue.7241, p.1036, 2000. ,
DOI : 10.1136/bmj.320.7241.1036
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC27343
EMIR: Effets indésirables des Médicaments: Incidence et Risque, sur les hospitalisations liées à un effet indésirable médicamenteux, 2007. ,
établissements de santé : premiers résultats d'une étude nationale N°398 de mai Disponible sur: http://drees.social-sante.gouv.fr 5, Les événements indésirables graves liés aux soins observés dans les Enquête Nationale sur les Evénements Indésirables graves liés aux Soins 2009 (ENEIS2): description des résultats 2009. Rapp Final À DREES Ministère Trav L'emploi Santé? Février, pp.3-3, 2005. ,
Co??t de la prise en charge des accidents vasculaires c??r??braux en France, Archives of Cardiovascular Diseases Supplements, vol.8, issue.2, pp.161-168, 2016. ,
DOI : 10.1016/S1878-6480(16)30330-5
Prise en charge des surdosages en antivitamines K, des situations ?? risque h??morragique et des accidents h??morragiques chez les patients trait??s par antivitamines K en ville et en milieu hospitalier, Journal des Maladies Vasculaires, vol.33, pp.70-71, 2008. ,
DOI : 10.1016/j.jmv.2008.07.036
Hématologie et transfusion. 2ème édition, 2008. ,
Utilisations des AVK Disponible sur : http://site.geht.org 13. revue prescrire article Fluindione : atteintes cutanées et rénales graves d'origine immunoallergique 35 (379) : 354. Disponible sur : http://formations.prescrire.org 14 ,
Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range, Journal of Thrombosis and Thrombolysis, vol.15, issue.3, pp.213-216, 2003. ,
DOI : 10.1023/B:THRO.0000011377.78585.63
Benchmark for Time in Therapeutic Range in Venous Thromboembolism: A Systematic Review and Meta-Analysis, PLoS ONE, vol.7, issue.9 ,
DOI : 10.1371/journal.pone.0042269.t004
Safety and efficacy of well managed warfarin, Thrombosis and Haemostasis, vol.113, issue.6, pp.1370-1377, 2015. ,
DOI : 10.1160/TH14-10-0859
Disponible sur : http://www.has-sante, 2014. ,
Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation, New England Journal of Medicine, vol.349, issue.11, pp.1019-1026, 2003. ,
DOI : 10.1056/NEJMoa022913
guidelines for the management of patients with atrial fibrillation: full text, Europace, vol.8, issue.9, pp.651-745, 2006. ,
Disponible sur, 2003. ,
Épidémiologie et facteurs de risque hémorragique des traitements par les antivitamines K. Sang Thromb Vaiss, pp.21-55, 2008. ,
Warfarin Anticoagulation and Outcomes in Patients With Atrial Fibrillation, Chest, vol.126, issue.6, pp.1938-1945, 2004. ,
DOI : 10.1378/chest.126.6.1938
fr -Avenant n°1 à la convention nationale Disponible sur : http://www.ameli.fr 28. bulletin amvf 8 novembre 2012 Clinique des anticoagulants.pdf. Disponible sur ,
Les cliniques d???anticoagulants sont-elles efficaces en France??? ??valuation des performances de six cliniques dans la gestion des traitements par antivitamines K, La Revue de M??decine Interne, vol.34, issue.9, pp.515-521, 2013. ,
DOI : 10.1016/j.revmed.2013.02.001
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation, Europace, vol.17, issue.10, pp.1467-507, 2015. ,
DOI : 10.1093/europace/euv309
A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays, Thrombosis Research, vol.115, issue.1-2, pp.9-18, 2005. ,
DOI : 10.1016/j.thromres.2004.07.001
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, The Lancet, vol.370, issue.9591, pp.949-956, 2007. ,
DOI : 10.1016/S0140-6736(07)61445-7
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, Journal of Thrombosis and Haemostasis, vol.5, issue.2, pp.2178-2185, 2007. ,
DOI : 10.1016/S0140-6736(07)61445-7
Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12, pp.1139-1151, 2009. ,
DOI : 10.1056/NEJMoa0905561
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation, pp.237-280, 2013. ,
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism, New England Journal of Medicine, vol.361, issue.24, pp.2342-2352, 2009. ,
DOI : 10.1056/NEJMoa0906598
URL : https://hal.archives-ouvertes.fr/ujm-00439704
A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II) Oral presentation from Session 332: Antithrombotic Therapy 1, 2011. ,
Avis du 17 décembre 2014 (DABIGATRAN) Disponible sur : http://www.has-sante ,
Idarucizumab for Dabigatran Reversal, New England Journal of Medicine, vol.373, issue.6, pp.511-531, 2015. ,
DOI : 10.1056/NEJMoa1502000
Avis du 17 décembre 2014 (RIVAROXABAN) Disponible sur : http://www.has-sante ,
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.10, pp.883-891, 2011. ,
DOI : 10.1056/NEJMoa1009638
URL : https://hal.archives-ouvertes.fr/hal-01038111
Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, vol.2010, issue.363, pp.2499-2510, 2010. ,
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, vol.2012, issue.366, pp.1287-1297, 2012. ,
Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation, European Heart Journal, vol.36, issue.28, pp.1805-1816, 2015. ,
DOI : 10.1093/eurheartj/ehv177
URL : https://hal.archives-ouvertes.fr/hal-01259326
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation, European Heart Journal, vol.37, issue.14, pp.1145-53, 2016. ,
DOI : 10.1093/eurheartj/ehv466
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study, The Lancet Haematology, vol.3, issue.1, pp.12-21, 2016. ,
DOI : 10.1016/S2352-3026(15)00257-4
Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51, Journal of the American College of Cardiology, vol.62, issue.4, pp.286-90, 2013. ,
DOI : 10.1016/j.jacc.2013.03.041
Avis du 17 décembre 2014 (APIXABAN) Disponible sur : http://www.has-sante ,
Apixaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.11, pp.981-992, 2011. ,
DOI : 10.1056/NEJMoa1107039
Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment, American Heart Journal, vol.159, issue.3, pp.348-353, 2010. ,
DOI : 10.1016/j.ahj.2009.08.026
Oral Apixaban for the Treatment of Acute Venous Thromboembolism, New England Journal of Medicine, vol.369, issue.9, pp.799-808, 2013. ,
DOI : 10.1056/NEJMoa1302507
URL : https://hal.archives-ouvertes.fr/hal-00932477
Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), Authors/Task Force Members Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Developed with the special contribution of the European Heart Rhythm Association (EHRA), pp.2369-429, 2010. ,
Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF), American Heart Journal, vol.151, issue.3, pp.713-722, 2006. ,
DOI : 10.1016/j.ahj.2005.04.017
Edoxaban versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.369, issue.22, pp.2093-104, 2013. ,
DOI : 10.1056/NEJMoa1310907
URL : https://hal.archives-ouvertes.fr/hal-00934699
Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry, Thrombosis and Haemostasis, vol.100, issue.1, p.26, 2008. ,
DOI : 10.1160/TH08-03-0193
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism, N Engl J Med. 10 oct, vol.369, issue.15, pp.1406-1421, 2013. ,
une étude de l'assurance maladie souligne la dynamique forte de ces nouveaux médicaments et la nécessité d'une vigilance accrue dans leur utilisation (27 novembre 2013) Disponible sur ,
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, European Heart Journal, vol.37, issue.38, pp.2893-962, 2016. ,
DOI : 10.1093/eurheartj/ehw210
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves, New England Journal of Medicine, vol.369, issue.13, pp.1206-1220, 2013. ,
DOI : 10.1056/NEJMoa1300615
Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation, Journal of the American Heart Association, vol.5, issue.2, p.3074, 2016. ,
DOI : 10.1161/JAHA.115.003074
Assessment of an education and guidance program for apixaban adherence in nonvalvular atrial fibrillation: the randomised AEGEAN study, 2015. ,
Disponible sur: http://www.escardio.org/static_file, EHRA-NOAC-card-A5.pdf 74. (France) C universitaire des enseignants de néphrologie, Moulin B, Peraldi M-N. Néphrologie. Ellipses, 2009. ,
Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature, Circulation, vol.126, issue.20, p.112, 2012. ,
DOI : 10.1161/CIRCULATIONAHA.112.115410
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. Circulation, pp.2325-2357, 2013. ,
Major Bleeding in Patients With Atrial??Fibrillation Receiving Apixaban or Warfarin, Journal of the American College of Cardiology, vol.63, issue.20, pp.2141-2148, 2014. ,
DOI : 10.1016/j.jacc.2014.02.549
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial, European Heart Journal, vol.35, issue.28, pp.1873-80, 2014. ,
DOI : 10.1093/eurheartj/ehu083
Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial, The American Journal of Medicine, vol.129, issue.8, pp.850-857, 2016. ,
DOI : 10.1016/j.amjmed.2016.02.028
Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial, Circulation, vol.126, issue.3, pp.343-351, 2012. ,
DOI : 10.1161/CIRCULATIONAHA.111.090464
Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures, Blood, vol.124, issue.25, pp.3692-3700, 2014. ,
DOI : 10.1182/blood-2014-08-595496
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263979
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial, European Heart Journal, vol.36, issue.20, pp.1264-72, 2015. ,
DOI : 10.1093/eurheartj/ehu463
du bénéfice/risque à court terme des nouveaux anticoagulants oraux (dabigatran, rivaroxaban) chez les patients débutant un traitement et non précédemment traités par des antivitamines K. Disponible sur ,
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation, Journal of the American Heart Association, vol.5, issue.6, p.3725, 2016. ,
DOI : 10.1161/JAHA.116.003725
www.thromboclic.fr. Un site pour l???accompagnement des m??decins dans l???utilisation des nouveaux anticoagulants oraux??: dabigatran et rivaroxaban, European Research in Telemedicine / La Recherche Europ??enne en T??l??m??decine, vol.4, issue.1, pp.3-7, 2015. ,
DOI : 10.1016/j.eurtel.2014.11.002
The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective ???Real-world??? Inception Cohort Study, The American Journal of Medicine, vol.128, issue.11, pp.1237-1243, 2015. ,
DOI : 10.1016/j.amjmed.2015.05.036
score, European Heart Journal - Cardiovascular Pharmacotherapy, vol.1, issue.3, pp.150-152, 2015. ,
DOI : 10.1093/ehjcvp/pvv012
Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists, Europace, vol.17, issue.5, pp.711-718, 2015. ,
DOI : 10.1093/europace/euu353
The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation, Annals of Internal Medicine, vol.151, issue.5, pp.297-305, 2009. ,
DOI : 10.7326/0003-4819-151-5-200909010-00003
Effects of Oral Anticoagulant Therapy in Medical Inpatients ???65??Years With Atrial Fibrillation, The American Journal of Cardiology, vol.117, issue.4, pp.590-595, 2016. ,
DOI : 10.1016/j.amjcard.2015.11.032
Consensus d'experts de la Société française de gériatrie et gérontologie et de la Société française de cardiologie, sur la prise en charge de la fibrillation atriale du sujet âgé, Gériatrie Psychol Neuropsychiatr Vieil, vol.11, issue.2, pp.117-143, 2013. ,
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial, The Lancet, vol.370, issue.9586, pp.493-503, 2007. ,
DOI : 10.1016/S0140-6736(07)61233-1
A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO), Age and Ageing, vol.36, issue.2, pp.151-157, 2007. ,
DOI : 10.1093/ageing/afl129
Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice, Age and Ageing, vol.44, issue.5, pp.874-882, 2015. ,
DOI : 10.1093/ageing/afv071
Individualized approaches to thromboprophylaxis in atrial fibrillation, American Heart Journal, vol.173, pp.143-158, 2016. ,
DOI : 10.1016/j.ahj.2015.10.021
New Oral Anticoagulants in Elderly Adults: Evidence from a Meta-Analysis of Randomized Trials, Journal of the American Geriatrics Society, vol.3, issue.Suppl 10, pp.857-864, 2014. ,
DOI : 10.1111/jgs.12799
Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials, European Journal of Heart Failure, vol.79, issue.11, pp.1192-1200, 2015. ,
DOI : 10.1002/ejhf.343
Meta-Analysis of Renal Function on the Safety and Efficacy of Novel Oral Anticoagulants for Atrial Fibrillation, The American Journal of Cardiology, vol.117, issue.1, pp.69-75, 2016. ,
DOI : 10.1016/j.amjcard.2015.09.046
Nonvitamin-K-Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Stroke, vol.43, issue.12, pp.3298-304, 2012. ,
DOI : 10.1161/STROKEAHA.112.673558